focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.825
Bid: 1.80
Ask: 1.85
Change: -0.125 (-6.41%)
Spread: 0.05 (2.778%)
Open: 1.95
High: 1.95
Low: 1.825
Prev. Close: 1.95
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

Wed, 03rd Apr 2024 10:47

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Genedrive PLC, up 57% at 5.90 pence, 12-month range 2.56p-34.90p. The molecular diagnostics company announces that the UK's National Institute for Health & Care Excellence has recommended in draft guidance that Genedrive's CYP2C19-ID test should be used as the point-of-care test of choice for ischemic stroke and transient ischaemic attack patients. Chief Executive Officer James Cheek comments: "We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for face, arms, speech and time, and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect....With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve US Food & Drug Administration approval and sales being realised from new customers in 2024 we feel there is growing momentum within the group's POC pharmacogenetic testing strategy."

----------

Corero Network Security PLC, up 15% at 10.36p, 12-month range 5.50p-10.65p. The cybersecurity provider specialising in distributed denial-of-service protection solutions wins a contract renewal worth over USD2 million over three years with an unnamed US-based software-as-a-service provider, expanding its partnership and marking one of Corero's "largest" single transactions to date. Corero says the deal reinforces its strong customer retention track record, while "significantly" enhancing the customer's distributed denial-of-service protection infrastructure. This ensure the "security and service availability of the SaaS provider's worldwide operations and reinforcing its resilience against the burgeoning range of cyberthreats". Corero Chief Executive Officer Carl Herberger comments: "We are committed to providing cutting-edge, reliable DDoS protection solutions to support our customers' growth and operational security and will continue to explore new business and mandate expansion opportunities as we aim to both broaden and strengthen our client portfolio."

----------

AIM - LOSERS

----------

Peel Hunt Ltd, down 5.1% at 120.00p, 12-month range 78.00p-142.00p. The investment bank expects a full-year loss as increasing costs offset a modest rise in revenue. In a trading statement for the year to March 31, Peel Hunt says revenue is expected to be consistent with market expectations at around GBP85.5 million, up 3.9% from GBP82.3 million last year. This growth comes despite equity capital markets "remaining challenging" throughout the financial year. Looking ahead, the firm expects market trading volumes to remain low until there are meaningful signs of recovery in the UK economy and fund outflows reverse. It notes whilst initial public offering activity in the UK remains muted, there has been more activity in Europe and sentiment towards IPOs is improving in the UK, with investors increasingly willing to engage in relation to high quality companies.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2021 11:34

Genedrive shares soar as files for UK approval of Covid testing kit

Genedrive shares soar as files for UK approval of Covid testing kit

Read more
22 Dec 2021 11:28

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Read more
9 Dec 2021 12:26

TRADING UPDATES: Genedrive's Covid test kit gets EU approval

TRADING UPDATES: Genedrive's Covid test kit gets EU approval

Read more
2 Dec 2021 10:37

AIM WINNERS & LOSERS: Digitalbox shares surge on earnings outlook

AIM WINNERS & LOSERS: Digitalbox shares surge on earnings outlook

Read more
29 Nov 2021 20:22

IN BRIEF: Genedrive shares soar on bid to get Covid test EU approval

IN BRIEF: Genedrive shares soar on bid to get Covid test EU approval

Read more
29 Nov 2021 15:13

Genedrive submits new Covid-19 test for EU certification

(Sharecast News) - Molecular diagnostics company Genedrive has submitted its new rapid point-of-care molecular Covid-19 test for CE-IVD certification in Europe, it announced on Monday.

Read more
16 Nov 2021 14:35

EXECUTIVE CHANGES: Countryside Properties and musicMagpie poach CFOs

EXECUTIVE CHANGES: Countryside Properties and musicMagpie poach CFOs

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
9 Nov 2021 15:02

Revenues fall, losses narrow for Genedrive

(Sharecast News) - Near-patient molecular diagnostics company Genedrive reported revenue of £0.7m in its final results on Tuesday, down from £1.1m year-on-year.

Read more
2 Nov 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
29 Sep 2021 18:23

TRADING UPDATES: Fulham Shore mulls dividend; LoopUp swings to loss

TRADING UPDATES: Fulham Shore mulls dividend; LoopUp swings to loss

Read more
29 Sep 2021 13:08

Genedrive gets CE-IVD marking for new system platform

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Wednesday that the new-generation 'Genedrive System' platform, which was developed to support the commercial launch of the 'Genedrive MT-RNR1' ID kit, had now received CE-IVD marking in anticipation of launch in the UK and the European Union.

Read more
23 Sep 2021 16:03

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
10 Sep 2021 16:14

TRADING UPDATES: Argo gets GBP18 million loan; Genedrive fundraises

TRADING UPDATES: Argo gets GBP18 million loan; Genedrive fundraises

Read more
31 Aug 2021 21:35

TRADING UPDATES: Jet2 in bumper Airbus order; Strix China factory live

TRADING UPDATES: Jet2 in bumper Airbus order; Strix China factory live

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.